The company said second-quarter revenue for the quarter ended December 31, 2025 was $295.9 million, flat from the prior year on both a reported and organic basis. Its adjusted operating margin was 31.1%, compared with 30.1% a year earlier.

1. 01

   The company said second-quarter revenue for the quarter ended December 31, 2025 was $295.9 million, flat from the prior year on both a reported and organic basis. Its adjusted operating margin was 31.1%, compared with 30.1% a year earlier.

2. 02

   Bio-Techne said GAAP operating income for the quarter rose 15% to $54.5 million ($47.4 million a year earlier), GAAP operating margin was 18.4% (16.0% a year earlier), and diluted earnings per share were $0.24 ($0.22 a year earlier).

3. 03

   The company said Protein Sciences segment revenue was $215.1 million, with an operating margin of 39.3% (41.2% a year earlier), and Diagnostics and Spatial Biology segment revenue was $81.2 million, with an operating margin of 10.4% (3.9% a year earlier).

4. 04

   Bio-Techne disclosed that for the six months ended December 31, 2025, net cash provided by operating activities was 109,996 (in thousands of dollars), net repayments of long-term debt were 86,000 (in thousands of dollars), and long-term debt fell from 346,000 (in thousands of dollars) as of June 30, 2025 to 260,000 (in thousands of dollars).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.